




RealRate

# PHARMACEUTICAL 2022

Deciphera Pharmaceuticals Inc  
Rank 282 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Deciphera Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Deciphera Pharmaceuticals Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 30% points. The greatest weakness of Deciphera Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 254%, being 21% points below the market average of 275%.

| Input Variable                              | Value in<br>1000 USD | Output Variable             | Value in<br>1000 USD |
|---------------------------------------------|----------------------|-----------------------------|----------------------|
| Assets, Current                             | 339,014              | Assets                      | 429,484              |
| Cost of Goods Sold                          | 2,932                | Liabilities                 | 124,764              |
| Intangible Assets                           | 0                    | Expenses                    | 396,225              |
| Liabilities, Current                        | 96,773               | Revenues                    | 96,148               |
| Liabilities, Non-Current                    | 27,991               | Stockholders Equity         | 304,720              |
| Other Assets                                | 81,860               | Net Income                  | -299,964             |
| Other Compr. Net Income                     | 40                   | Comprehensive Net Income    | -299,944             |
| Other Expenses                              | 0                    | BaseVar                     | 523,387              |
| Other Liabilities                           | 0                    | ECR before LimitedLiability | 131%                 |
| Other Net Income                            | 113                  | Economic Capital Ratio      | 254%                 |
| Other Revenues                              | 96,148               |                             |                      |
| Property and Equipment                      | 8,610                |                             |                      |
| Research and Development                    | 257,040              |                             |                      |
| Selling, General and Administrative Expense | 136,253              |                             |                      |